Literature DB >> 22135475

Bayesian Experimental Design for Long-Term Longitudinal HIV Dynamic Studies.

Yangxin Huang1, Hulin Wu.   

Abstract

The study of HIV dynamics is one of the most important developments in recent AIDS research for understanding the pathogenesis of HIV-1 infection and antiviral treatment strategies. Currently a large number of AIDS clinical trials on HIV dynamics are in development worldwide. However, many design issues that arise from AIDS clinical trials have not been addressed. In this paper, we use a simulation-based approach to deal with design problems in Bayesian hierarchical nonlinear (mixed-effects) models. The underlying model characterizes the long-term viral dynamics with antiretroviral treatment where we directly incorporate drug susceptibility and exposure into a function of treatment efficacy. The Bayesian design method is investigated under the framework of hierarchical Bayesian (mixed-effects) models. We compare a finite number of feasible candidate designs numerically, which are currently used in AIDS clinical trials from different perspectives, and provide guidance on how a design might be chosen in practice.

Entities:  

Year:  2008        PMID: 22135475      PMCID: PMC3225901          DOI: 10.1016/j.jspi.2007.05.019

Source DB:  PubMed          Journal:  J Stat Plan Inference        ISSN: 0378-3758            Impact factor:   1.111


  15 in total

1.  Population HIV-1 dynamics in vivo: applicable models and inferential tools for virological data from AIDS clinical trials.

Authors:  H Wu; A A Ding
Journal:  Biometrics       Date:  1999-06       Impact factor: 2.571

2.  Bayesian experimental design for nonlinear mixed-effects models with application to HIV dynamics.

Authors:  Cong Han; Kathryn Chaloner
Journal:  Biometrics       Date:  2004-03       Impact factor: 2.571

3.  Design of HIV viral dynamics studies.

Authors:  I C Marschner
Journal:  Stat Med       Date:  1998-11-15       Impact factor: 2.373

4.  Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.

Authors:  A Molla; M Korneyeva; Q Gao; S Vasavanonda; P J Schipper; H M Mo; M Markowitz; T Chernyavskiy; P Niu; N Lyons; A Hsu; G R Granneman; D D Ho; C A Boucher; J M Leonard; D W Norbeck; D J Kempf
Journal:  Nat Med       Date:  1996-07       Impact factor: 53.440

5.  Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system.

Authors:  Yangxin Huang; Dacheng Liu; Hulin Wu
Journal:  Biometrics       Date:  2006-06       Impact factor: 2.571

6.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

7.  Modeling long-term HIV dynamics and antiretroviral response: effects of drug potency, pharmacokinetics, adherence, and drug resistance.

Authors:  Hulin Wu; Yangxin Huang; Edward P Acosta; Susan L Rosenkranz; Daniel R Kuritzkes; Joseph J Eron; Alan S Perelson; John G Gerber
Journal:  J Acquir Immune Defic Syndr       Date:  2005-07-01       Impact factor: 3.731

8.  Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.

Authors:  Edward P Acosta; Hulin Wu; Scott M Hammer; Song Yu; Daniel R Kuritzkes; Ann Walawander; Joseph J Eron; Carl J Fichtenbaum; Carla Pettinelli; Denise Neath; Elaine Ferguson; Alfred J Saah; John G Gerber
Journal:  J Acquir Immune Defic Syndr       Date:  2004-11-01       Impact factor: 3.731

9.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.

Authors:  D D Ho; A U Neumann; A S Perelson; W Chen; J M Leonard; M Markowitz
Journal:  Nature       Date:  1995-01-12       Impact factor: 49.962

10.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.